Erratum to: Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)
نویسندگان
چکیده
The paper contains an incorrect funding statement within the Acknowledgements section. The statement currently reads: Sponsorship for this study was funded by Gilead. No funding or sponsorship was received for publication of this article. The statement should read: Sponsorship for this study and article processing charges for the manuscript were funded by Gilead. Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
منابع مشابه
Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study)
INTRODUCTION We aimed to assess if ranolazine would improve angina symptoms among patients with documented myocardial ischemia. METHODS Eligible subjects had chronic stable angina and at least one coronary stenosis with fractional flow reserve (FFR) ≤0.80 or at least one chronic total occlusion (CTO) without attempted revascularization. Subjects were randomized to oral ranolazine 500 mg twice...
متن کاملUtility of ranolazine in chronic stable angina patients
Chronic stable angina is a debilitating illness affecting at least 6.6 million US residents. Despite being optimally treated by pharmacotherapy and revascularization up to 26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in angina patients. Several new investigational medications are being tested for chronic angina. Advances in understanding of myocardi...
متن کاملImpact of ranolazine on myocardial metabolic ischemia detected by phosphorus-31 magnetic resonance spectroscopy
Background Ranolazine (RAN) is a novel late sodium current inhibitor, effective in treating angina pectoris in patients with chronic stable CAD. Its therapeutic effectiveness is not well understood. It is thought to reduce myocardial energy utilization by enhancing diastolic relaxation and by increasing myocardial blood flow. The purpose of the present study is to define the mechanism for the e...
متن کاملResolution of Angina Pectoris and Improvement of the Coronary Flow Reserve after Ranolazine Treatment in a Woman with Isolated Impaired Coronary Microcirculation
In a 61-year-old woman with well controlled arterial hypertension, hypercholesterolemia, and smoke and suffering from recurrent angina pectoris despite angiographically normal epicardial coronary vessels and maximal therapy, the replacement of nitrates with novel antiangina drug ranolazine, after 6-month therapy, induced a complete relief of angina and a relevant rising of the transthoracic Dop...
متن کاملAnti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
OBJECTIVES The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration. BACKGROUND Fatty acids rise precipitously in response to stress, including acute myocardial ischemia. Ranolazine is believed to partially inhibi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 6 شماره
صفحات -
تاریخ انتشار 2017